GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

The UK big pharma company will pay $1.2bn upfront for Boston’s subsidiary BP Asset IX, which will give the company access to efimosfermin. GSK has also agreed to pay additional milestone ...

GSK will acquire liver-disease treatment efimosfermin from Boston Pharmaceuticals for up to $2 billion to expand its portfolio. The British pharma giant said Wednesday that it will pay the U.S ...

However, this narrative is difficult to apply to Flovent since when GSK removed the brand drug in favor of a generic version, the company cut the price by almost $100, from $274 to $178.

As part of the deal, GSK will acquire Boston Pharmaceuticals’ subsidiary BP Asset IX to gain full rights to the drug. Efimosfermin, aimed at treating steatotic liver disease, is in late-stage ...

Only a few days out of the European Association for the Study of the Liver annual meeting, the metabolic dysfunction-associated steatohepatitis (MASH) space continues to grab headlines, with GSK plc ...

Under the agreement to acquire Boston Pharmaceuticals' lead asset Efimosfermin, GSK will pay $1.2 billion upfront followed by additional success-based milestone payments totalling $800 million.

Financial considerations Under the terms of the agreement, GSK will acquire BP Asset IX, Inc., a subsidiary of Boston Pharmaceuticals, to access efimosfermin.